Education
About Us
Working with TipRanks
Follow Us
ConvaTec (GB:CTEC)
LSE:CTEC
CTEC Stock Chart & Stats
230.80 p
1.06 p(0.47%)
At close: 4:00 PM EST
230.80 p
1.06 p(0.47%)
Day’s Range― - ―
52-Week Range209.40 p - 311.20 p
Previous CloseN/A
Volume85.46K
Average Volume (3M)6.27M
Market Cap
£4.75B
Enterprise Value7.85B
Total Cash (Recent Filing)£75.03M
Total Debt (Recent Filing)£1.61B
Price to Earnings (P/E)37.1
Beta0.85
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.11%
Share Statistics
EPS (TTM)0.07
Shares Outstanding1,954,852,000
10 Day Avg. Volume5,278,857
30 Day Avg. Volume6,266,139
Financial Highlights & Ratios
PEG Ratio-7.34
Price to Book (P/B)4.36
Price to Sales (P/S)2.66
P/FCF Ratio19.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£317.75Price Target Upside37.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.2
Revenue Forecast (FY)£2.57B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueConvaTec's core model sells repeat-use consumables across chronic-care categories, creating predictable recurring revenue tied to ongoing patient needs and reimbursement. That stickiness supports durable top-line visibility, recurring cash flow and easier scaling of margin-accretive initiatives over months to years.
Consistent Organic Growth And Margin ExpansionThe company has delivered multi-year organic growth and sustained operating margin expansion (cumulative ~460bps since 2021). Persistent demand and disciplined cost management imply structural improvement in operating leverage that supports durable earnings growth and the ability to invest in pipeline and capacity over the medium term.
Strong Cash Generation And Capital AllocationRobust free cash flow and high conversion enable repeat buybacks, growing dividends and funding of growth CapEx without diluting shareholders. Consistent FCF provides financial flexibility to support capacity expansion and product launches, underpinning sustainable investment in high-return initiatives over the next few years.
Bears Say
Rising Leverage And Net DebtLeverage has stepped up materially, reducing balance sheet flexibility and increasing sensitivity to interest rates or earnings volatility. Higher net debt limits room for opportunistic M&A or cushioning against shocks, and maintaining targets (circa 2x net debt/EBITDA) requires consistent cash generation and disciplined allocation.
FDA Warning Letter On Complaints/CAPAA regulatory warning on quality systems forces prioritized remediation, diverting management focus and requiring process, documentation and potentially capital fixes. If unresolved, it risks inspections, delays for new product rollouts, and could constrain reimbursement or hospital adoption—structural execution risk until closed.
InnovaMatrix Reimbursement Hit And ImpairmentA severe CMS price reduction and related impairment reveal material reimbursement and channel risk for acquired product lines. This directly lowers revenue and profitability for that portfolio, complicates integration economics for M&A, and underscores exposure to policy-driven payor changes that can persist and depress returns on similar assets.
ConvaTec News
CTEC FAQ
What was ConvaTec’s price range in the past 12 months?
ConvaTec lowest share price was 209.40 p and its highest was 311.20 p in the past 12 months.
What is ConvaTec’s market cap?
ConvaTec’s market cap is £4.75B.
When is ConvaTec’s upcoming earnings report date?
ConvaTec’s upcoming earnings report date is Aug 04, 2026 which is in 148 days.
How were ConvaTec’s earnings last quarter?
ConvaTec released its earnings results on Feb 24, 2026. The company reported 0.072 p earnings per share for the quarter, missing the consensus estimate of 0.075 p by -0.003 p.
Is ConvaTec overvalued?
According to Wall Street analysts ConvaTec’s price is currently Undervalued.
Does ConvaTec pay dividends?
ConvaTec pays a Semiannually dividend of 1.399 p which represents an annual dividend yield of 2.11%. See more information on ConvaTec dividends here
What is ConvaTec’s EPS estimate?
ConvaTec’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ConvaTec have?
ConvaTec has 1,954,852,000 shares outstanding.
What happened to ConvaTec’s price movement after its last earnings report?
ConvaTec reported an EPS of 0.072 p in its last earnings report, missing expectations of 0.075 p. Following the earnings report the stock price went up 10.396%.
Which hedge fund is a major shareholder of ConvaTec?
Currently, no hedge funds are holding shares in GB:CTEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ConvaTec Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
£317.75 (37.67% Upside)
£317.75 (37.67% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.61%
12-Months-Change
Fundamentals
Return on Equity
12.73%
Trailing 12-Months
Asset Growth
-4.01%
Trailing 12-Months
Company Description
ConvaTec
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.
CTEC Stock 12 Month Forecast
Average Price Target
317.75 p
▲(37.67% Upside)
Technical Analysis
Options Prices
Currently, No data available
---